Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients

Multiple myeloma (MM) is an incurable disease with a limited life expectancy of five years from diagnosis. Uncontrolled disease or infections are the main causes of mortality. Daratumumab, a monoclonal antibody against CD38, is approved to treat patients with MM. Its target, CD38, is expressed not o...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Front Oncol
Главные авторы: Cottini, Francesca, Huang, Ying, Williams, Nita, Bumma, Naresh, Khan, Abdullah M., Chaudhry, Maria, Devarakonda, Srinivas, Efebera, Yvonne A., Benson, Don M., Rosko, Ashley E.
Формат: Artigo
Язык:Inglês
Опубликовано: Frontiers Media S.A. 2021
Предметы:
Oncology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7917249/
https://ncbi.nlm.nih.gov/pubmed/33659205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.575168
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы